Targeting specific immune cells to improve cancer treatment
Immunotherapy to deplete key Treg subsets in solid tumors
['FUNDING_SBIR_2'] · SONOVAL LLC · NIH-11006042
This study is testing a new treatment that aims to help your immune system fight solid tumors like lung cancer and melanoma by targeting certain cells that block its natural response, and it’s designed to be safer and more effective than previous options.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SONOVAL LLC (nih funded) |
| Locations | 1 site (GAITHERSBURG, UNITED STATES) |
| Trial ID | NIH-11006042 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new immunotherapy that aims to deplete certain regulatory T cells (Tregs) in solid tumors, such as non-small cell lung cancer and melanoma. These Tregs can inhibit the body's natural anti-tumor immune response, making it harder for patients to benefit from existing treatments like checkpoint inhibitors. The approach involves creating a modified version of a previously used drug, Ontak, which has been improved to reduce side effects while effectively targeting Tregs. By enhancing the immune response against tumors, this therapy could potentially lead to better treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with solid tumors, particularly those who have not responded well to current immunotherapies.
Not a fit: Patients with tumors that do not involve Treg suppression or those who have already had significant adverse reactions to similar therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve survival rates for patients with solid tumors.
How similar studies have performed: Previous research has shown promise with Treg-depleting therapies, but this specific approach with the modified Ontak is novel and aims to address past limitations.
Where this research is happening
GAITHERSBURG, UNITED STATES
- SONOVAL LLC — GAITHERSBURG, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUZDAK, PETER DAVID — SONOVAL LLC
- Study coordinator: SUZDAK, PETER DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents